Hanmi promotes clinical use of Keytruda & FLX475

FLX475, the world's first CCR4 target material introduced by a US bio company

Clinical cooperation and supply contract with MSD, free supply of clinical Keytruda

Phase II begins for Korean-Chinese gastric cancer patients in the first half of next year

Hanmi is entering a phase II clinical trial that uses a combination of CCR4 target oral immuno-cancer drug (FLX475), which is being developed in Korea, and MSD's immuno-cancer drug Keytruda (Pembrolizumab).

 

To this end, Hanmi announced on the 15th that it has signed a contract with MSD to supply Keytruda for clinical cooperation and clinical cooperation with FLX475-Keytruda.

 

In the first half of next year, Hanmi plans to start phase II in Korea and China, which measures the efficacy and safety of combination therapy for gastric cancer patients in Korea and China.

 

Keytruda, which is necessary for clinical use, is provided by MSD for free.

 

FLX475 is the first oral regulatory T-cell inhibitor developed by US biotechnology company RAPT Therapeutics, and Hanmi secured exclusive rights for development and commercialization in China, including Korea, Taiwan, and Hong Kong by transferring this candidate substance from RAPT Therapeutics last December.

 

Although the prevalence of gastric cancer in Korea is the second largest among all carcinomas, there are limited known appropriate treatments.

 

Hanmi expects this clinical trial to be a test that can confirm the value of the combination therapy of FLX475 and Keytruda in the field of gastric cancer.

 

Se-Chang Kwon, President of Hanmi, said, "As Korea is the country with the highest incidence of gastric cancer in the world, the clinical development of these two drugs is expected to be an innovative treatment option for patients in need of treatment.

 

We will do our best to obtain rapid development and approval." Hanmi is currently building and developing around 30 innovative new drug pipelines in the fields of metabolic diseases, anticancer and rare diseases such as NASH, and is continuing its efforts to expand its innovative portfolio of anticancer drugs through open innovation.

 

Based on multilateral cooperation with various partners, the anticancer pipeline will be further strengthened.